Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BioSyent Releases Results for Q1 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: GlobeNewswire - 28 May 2020 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MISSISSAUGA, Ontario, May 28, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key highlights include:
“Q1 2020 was a record quarter for our Canadian Pharmaceutical Business with growth from across our product portfolio,” commented Mr. René Goehrum, President and CEO of BioSyent. “We saw solid sales growth in the months of January and February 2020 and exceptional sales growth in the month of March 2020 at the outset of the COVID-19 pandemic in Canada. The increased sales activity in the latter part of March was largely due to a short-term surge in consumer demand for certain products and some accumulation of safety stocks by wholesalers, pharmacies, and hospitals in response to COVID-19 uncertainty. While we are managing the challenges of the current business environment, we nonetheless remain focused on the long-term and continue to make investments in future growth as we prepare for the Canadian launch of the new Tibella® women’s health product and the Combogesic® pain management product. I look forward to reporting on our progress over the coming months.” The CEO’s presentation on the Q1 2020 Results is available at the following link: www.biosyent.com/q1-20/. The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2020 and 2019 will be posted on www.sedar.com on May 28, 2020. For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com. PDF Available: http://ml.globenewswire.com/Resource/Download/e227027b-0556-42e8-b61a-bc7c16d53909 PDF Available: http://ml.globenewswire.com/Resource/Download/ad63ea41-4f83-4e3b-86a2-3690270c311c About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units. As of the date of this press release, the Company has 12,808,170 common shares outstanding.
For further information please contact: Mr. René C. Goehrum This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2020 GlobeNewswire | Back to overview list |